MetaCap

Aardvark Therapeutics (AARD) vs Adicet Bio (ACET)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adicet Bio (ACET) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 77.8% versus a loss of 90.2%. Aardvark Therapeutics is the larger company by market cap ($20.2 million vs $20.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

AARD-90.15%ACET-77.78%
+77%-11%-98%
Nov 21, 20251 yearNov 20, 2026
AARD-93.06%ACET-86.52%
+28%-35%-99%
Feb 10, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

AARD versus ACET key metrics
MetricAARDACET
Share price$0.9226$2.14
Market cap$20.20M$20.03M
1-day change-7.74%-13.01%
YTD return-92.97%-74.58%
1-year return-90.15%-77.78%
5-year return—-98.58%
EPS (TTM)$-3.33$-7.53
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$0—
Net income (latest FY)$-57.59M$-116.80M
52-week high$16.60$11.15
52-week low$0.90$2.12
Distance from 52-week high-94.44%-80.81%
Analyst consensusbuystrong_buy
Avg. price target upside+1104.21%+1527.57%
Average volume643.53K271.05K
Shares outstanding21.89M9.36M
Employees28102
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ACET has outperformed AARD by 12.4 percentage points over the past year.

About Aardvark Therapeutics

AARD stock →

Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

AARD vs ACET FAQ

Which is bigger, Aardvark Therapeutics or Adicet Bio?

Aardvark Therapeutics (AARD) is larger, with a market capitalization of $20.20M compared with $20.03M for Adicet Bio (ACET).

Which stock has performed better over the past year, AARD or ACET?

ACET returned -77.78% over the past 12 months, compared with -90.15% for AARD (price return, excluding dividends). Past performance does not predict future results.

Are Aardvark Therapeutics and Adicet Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons